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Topiramate in the treatment of severe myoclonic
epilepsy in infancy
M. NIETO-BARRERA, R. CANDAU, M. NIETO-JIMENEZ, A. CORREA & L. RUIZ DEL PORTAL
Paediatric Neurology Unit, Hospital Infantil Universitario “Virgen del Rocio”, Sevilla, Spain
The aim of this study was to assess the effectiveness of topiramate (TPM) as an add-on regimen in reducing seizure rate in a
population sample of patients diagnosed with severe myoclonic epilepsy in infancy (SME). Eighteen patients were evaluated.
The mean observation time was 10.5 months (range, 6–18 months). Seizure frequency and type were recorded. Topiramate
was administered as an add-on regimen at a starting dose of 1 mg kg−1 and titrated to a maximum of 6–8 mg per kg per day.
Different escalation rates were used, mainly weekly or fortnightly increments of dose. Three patients (16.6%) became seizure
free, and 10 (55.6%) had a >50% reduction in seizure frequency: six of them (22.2%) achieved a reduction greater than 75%.
Side-effects were observed in nine patients, eight with a weekly titration schedule and one with a fortnightly schedule. TPM is
effective as adjunctive therapy for SME. Side-effects were mild and transient, generally related to rapid dosage titration.
c© 2000 BEA Trading Ltd
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INTRODUCTION
Severe myoclonic epilepsy in infancy (SME) is a rare
epileptic syndrome first defined by Dravet et al. in
19821 and included as a syndrome in the Interna-
tional Classification of Epilepsy and Epileptic Syn-
dromes (ICE) in 1989 under the heading of epileptic
syndromes undetermined as to whether they are fo-
cal or generalized2. This type of epilepsy is very re-
sistant to all forms of treatment including steroids. A
transient response was observed with intravenous im-
munoglobulin (IVIG) therapy3. Topiramate (TPM) is
a new antiepileptic drug with multiple mechanisms
of action and a broad therapeutic spectrum4–6. Data
from a recent meta-analysis suggested that TPM was
possibly one of the most potent new drugs7. Indeed,
TPM is effective in the treatment of partial refrac-
tory epilepsies8–10, and in severe epileptic syndromes
such as Lennox–Gastaut syndrome11, 12 and Infantile
Spasms13. We report our observations of TPM therapy
in a group of patients with SME refractory to various
treatments.
MATERIALS AND METHODS
From October 1984 to October 1998 we collected 18
patients. The group of patients included eight males
and 10 females with ages ranging from 2 to 22 years
(mean age, 13.3 years) diagnosed with SME accord-
ing to the following criteria14: (1) no past medical his-
tory, (2) seizure onset in the first year of life, usually
as atypical febrile convulsions, or generalized clonic
seizures, (3) myoclonic, and/or partial and/or atypical
absence seizures between 2 and 4 years of age, (4)
a normal interictal EEG at the beginning, (5) EEG
recordings within the second year of life showing in-
terictal generalized spike-and-wave complexes and/or
photosensitive generalized polyspikes. Focal back-
ground anomalies may be present as well, and (6)
normal initial psychomotor development which be-
came delayed from the second year. Family history
of epilepsy or refractoriness to anticonvulsant therapy
also contributes to the diagnosis. Diagnosis was made
retrospectively in seven patients and prospectively
in 11.
All patients were considered refractory having
been treated with a mean of 6.7 AEDs (range, 3–8).
Eight patients were treated with IVIG and the other
two with adrenocorticotropic hormone (ACTH). All
patients were in pharmacological treatment at the time
of the study with one or several antiepileptic drugs
(AEDs) (median, 2.2 AEDs). Three patients were on
single-drug therapy, nine on double therapy, five on
triple therapy, and one received four drugs. During
a 3-month period this treatment was unchanged and
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Table 1: Demographics. Seizure number, types, and previous treatments.
No Age S Age 1st Seizure 1st seizure type Actual seizures Neuropsychological status Previous AEDs
1 4 yr 4 mo M 6 mo FS unilateral GTCS MR moderate VPA
2 5 yr 2 mo F 6 mo FS GTC prolonged GTCS MR moderate VPA
ABS CLB
3 14 yr M 7 mo FS GTC prolonged GTCS MR mild VPA
CLB
4 12 yr F 5 mo FS unilateral GTCS MR severe VPA
Hypotonia PRM
LTG
5 15 yr F 5 mo FS unilateral CPS MR mild VPA
CLB
6 17 yr M 5 mo GTC prolonged GTCS MR severe PB
MYOCL Hypotonia LTG
DPZ
7 3 yr 10 mo M 6 mo FS unilateral GTCS MR moderate VPA
ABS
8 22 yr F 4 mo FS unilateral GTCS MR severe PRM
LTG
9 3 yr 9 mo M 5 mo FS GTC prolonged GTCS MR mild VPA
CPS CZP
10 22 yr F 3 mo FS unilateral GTCS MR moderate VPA
SPS unilateral Hypotonia PB
ABS CBZ
MYOCL
11 18 yr F 5 mo GTC prolonged GTCS MR severe VPA
ABS CLB
12 2 yr 8 mo M 7 mo FS GTC prolonged GTCS MR mild VPA
13 17 yr F 4 mo FS unilateral GTCS MR severe PRM
CPS VGB
CLB
14 22 yr M 4 mo FS unilateral GTCS MR moderate VPA
CPS CLB
15 22 yr F 5 mo FS unilateral CPS MR severe VPA
Hypotonia LTG
CZP
PB
16 2 yr 3 mo M 4 mo FS unilateral GTCS MR mild VPA
PRM
17 14 yr F 5 mo FS GTC prolonged GTCS MR severe VPA
CPS PRM
CZP
18 9 yr 5 mo F 7 mo FS GTC prolonged CPS MR moderate VPA
ABS PRM
Abbreviations: ABS, absence seizure; CBZ, carbamazepine; CLB, clobazam; CPS, complex partial seizure; CZP, clonazepam; DZP,
diazepam; F, female; FS, febrile seizure; GTCS, generalized tonic–clonic seizure; LTG, lamotrigine; M, male; MYOCL, myoclonic seizure;
MR, mentally retarded; PRM, primidone; PB, phenobarbital; SPS, simple partial seizure; VPA, valproate; VGB, vigabatrin.
seizure frequency and type were recorded. Treatment
was optimized when TPM was initiated. Demograph-
ics and clinical situation prior to TPM are shown in
Table 1.
Three types of titration schedules were performed.
In five cases the schedule was started with 0.5–1 mg
kg−1, and the dose was doubled every week. In four
cases a starting dose of 1 mg kg−1 was followed by
weekly increments of 1 mg kg−1. In nine cases the
schedule was started with 1 mg kg−1 and increased by
1 mg kg−1 every 2 weeks for 12 weeks. The maximum
dosage in all cases was 6–8 mg kg−1. Seizure rate and
types, adverse effects and EEG findings were noted
during the titration stage and the subsequent follow-up
ranging from 6 to 18 months (mean, 10.5 months). As-
sessment of efficacy is essentially based on a reduction
in seizure rate greater than 50%, but seizure suppres-
sion and reductions greater than 75% were separate for
the analysis.
RESULTS
Before treatment eight patients presented only one
type of seizure, 10 had two types and one patient had
four seizure types. Generalized tonic–clonic seizures
were the most frequent type being present in 15
patients, eight patients had partial seizures (mainly
partial motor seizures), five patients had atypical ab-
sences and three patients had myoclonic seizures.
Seizure frequency varied between 1 and 32 per month.
Table 2 specifies seizure type, number, and EEG find-
592 M. Nieto-Barrera et al.
Table 2: Observation period pre-topiramate treatment.
No Weight (kg) Actual seizures No seizures in prior 3 mo EEG before TPM AEDs prior to TPM
1 22 GTCS 4 Generalized slow S-W VPA 41 mg kg−1
2 24.5 GTCS 11 Generalized slow S-W & VPA 30 mg kg−1
ABS >100 PS CLB 0.5 mg kg−1
3 36.5 GTCS 90 Generalized slow S-W & VPA 75 mg kg−1
PS CLB 1 mg kg−1
4 46 GTCS 4 Generalized slow S-W & VPA 18 mg kg−1
PS PRM 8 mg kg−1
LTG 4.5 mg kg−1
5 43 CPS 7 Generalized slow S-W & VPA 30 mg kg−1
PS CLB 0.3 mg kg−1
6 59 GTCS 30 Generalized slow S-W& PB 5 mg kg−1
MYOCL >100 PS LTG 5 mg kg−1
DPZ 0.5 mg kg−1
7 22.5 GTCS 3 Generalized slow S-W & VPA 66 mg kg−1
ABS 12 PS
8 45 GTCS 83 Slow S-W predominantly PRM16 mg kg−1
left hemisphere LTG 9 mg kg−1
9 14 GTCS 7 Slow S-W predominantly VPA 10 mg kg−1
CPS 30 right hemisphere CZP 0.1 mg kg−1
10 55 GTCS 20 Generalized slow S-W & VPA 18 mg kg−1
SPS unilateral 3 PS PB 1.8 mg kg−1
ABS 10 CBZ 12 mg kg−1
MYOCL 90
11 53 GTCS 78 Slow S-W predominantly VPA 38 mg kg−1
ABS 6 right hemisphere CLB 0.25 mg kg−1
12 14 GTCS 9 Generalized slow S-W VPA 40 mg kg−1
13 48 GTCS 3 Slow S-W predominantly PRM 10 mg kg−1
CPS 15 left hemisphere VGB 52 mg kg−1
CLB 1 mg kg−1
14 82 GTCS 12 Generalized slow S-W VPA 18.2 mg kg−1
CPS 3 CLB 0.2 mg kg−1
15 80 CPS 9 Generalized slow S-W VPA 22 mg kg−1
LTG 5 mg kg−1
CZP 0.1 mg kg−1
PB 2 mg kg−1
16 12 GTCS 6 Generalized slow S-W VPA 30 mg kg−1
PRM 15 mg kg−1
17 54 GTCS 90 Slow S-W predominantly VPA 30 mg kg−1
CPS 5 left hemisphere PRM 5 mg kg−1
CZP 0.1 mg kg−1
18 42 CPS 6 Generalized slow S-W VPA 38.5 mg kg−1
ABS >100 PRM 6 mg kg−1
Abbreviations: ABS, absence seizure; CBZ, carbamazepine; CLB, clobazam; CPS, complex partial seizure; CZP, clonazepam; DZP,
diazepam; FS, febrile seizure; GTCS, generalized tonic–clonic seizure; LTG, lamotrigine; MYOCL, myoclonic seizure; PB, phenobarbital;
PRM, primidone; PS, polyspikes; SPS, simple partial seizure; S-W, spike-and-wave; VPA, valproate; VGB, vigabatrin.
ings in every case.
When topiramate was added, 14 patients were on
valproate, three on monotherapy. At the end of the
study, 72% of patients reached a >50% reduction in
seizure rate, 50% had a reduction rate >75% and
16.6% were seizure free. Table 3 shows results dur-
ing TPM therapy. All these patients started to improve
from the titration period. Figure 1 presents response
rate by seizure type. Response was slightly better in
partial than in generalized seizures. The most dramatic
response was with atypical absence seizures in which
a total response rate was achieved. A better response
rate was observed if the patient had one type of seizure
or a combination of partial or generalized with atypical
absence seizures. Response to TPM has no apparent
relationship with the titration schedule, the maximal
dose or time since diagnosis.
Adverse effects were observed mainly during the
fourth and sixth weeks of treatment. Usually these
were minor and lasted 10–14 days except for weight
loss, which persisted longer. These occurred in most
cases with a weekly increase and exceptionally when
the dose was increased every fortnight. In no case was
TPM withdrawn.
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Table 3: Topiramate treatment. Results.
No. TPM Scalation No seizures during Maintenance AEDs associated Follow-up time Actual state Adverse effects
start dose type first 2 months doses
1 25 mg A 0 200 VPA 41 mg kg−1 12 1 per 3 mo Somnolence
1 mg kg−1 Red >75% Weight loss
Motor incoordination
2 25 mg A 5 GTCS 200 VPA 40 mg kg−1 12 1 per mo Somnolence
1 mg kg−1 >100 ABS Red >50% Weight loss
Midriasis
3 25 mg A 5 GTCS 200 VPA 27 mg kg−1 12 30 per mo Anorexia
0.7 mg kg−1 39 CPS No effect Restlessness
Impulsivity
4 25 mg A 4 GTCS 400 PRM 8 mg kg−1 12 1 per day Anorexia
0.5 mg kg−1 LTG 4.5 mg kg−1 Increment Weight loss
seizure rate Somnolence
5 25 mg A 0 400 VPA 30 mg kg−1 12 Seizure free Drooling
0.5 mg kg−1 Apathic
6 50 mg B 20 GTCS 400 PB 5 mg kg−1 12 10 per mo Anorexia
1 mg kg−1 60 MYOCL DPZ 0.5 mg kg−1 No effect Somnolence
Sphincter incontinence
7 25 mg B 2 GTCS 150 VPA 66.6 mg kg−1 12 Seizure free Weight loss
1 mg kg−1 Anorexia
8 50 mg B 36 GTCS 600 PRM 16 mg kg−1 10 13 per mo Apathic
21 mg kg−1 Red >50%
9 12.5 mg B 10 GTCS 150 VPA 15 mg kg−1 8 1–2 per mo —
1 mg kg−1 7 CPS CZP 0.1 mg kg−1 Red >75%
10 50 mg C 5 GTCS 500 VPA 18 mg kg−1 18 3–4 per mo —
1 mg kg−1 10 MYOCL CBZ 16 mg kg−1 Red >50%
11 100 mg C 6 GTCS 500 VPA 38 mg kg−1 18 1–2 per mo —
2 mg kg−1 8 ABS CLB 0.25 mg kg−1 Red >75%
12 12.5 mg C 2 GTCS 100 VPA 40 mg kg−1 14 1–2 per mo —
1 mg kg−1 Red >75%
13 50 mg C 3 GTCS 350 PRM 10 mg kg−1 7 1 per 7 mo —
1 mg kg−1 0 CPS CLB 1 mg kg−1 Red >75%
14 50 mg C 1 GTCS 400 VPA 18.2 mg kg−1 7 1 per wk —
0.6 mg kg−1 2 CPS CLB 0.2 mg kg−1 Red >25%
15 50 mg C 3 CPS 400 VPA 20 mg kg−1 6 1–2 per mo —
0.75 mg kg−1 LTG 2.5 mg kg−1 Red >50%
16 12.5 mg C 3 GTCS 100 VPA 25 mg kg−1 6 1 per mo Somnolence
1 mg kg−1 PRM 15 mg kg−1 Red >25%
17 50 mg C 20 GTCS 400 VPA 30 mg kg−1 6 1–2 per mo —
1 mg kg−1 2 CPS PRM 5 mg kg−1 Red >75%
18 25 mg C 1 CPS 200 VPA 38.5 mg kg−1 6 Seizure free —
0.6 mg kg−1 25 ABS PRM 6 mg kg−1
Titration schedule: A, doubling starting dose every week; B, increasing dose by 1 mg per kg of body weight every week; C, increasing dose by
1 mg per kg of body weight every 2 weeks.
Abbreviations: ABS, absence seizure; CBZ, carbamazepine; CLB, clobazam; CPS, complex partial seizure; CZP, clonazepam; DZP,
diazepam; GTCS, generalized tonic–clonic seizure; LTG, lamotrigine; MYOCL, myoclonic seizure; PB, phenobarbital; PRM, primidone;
SPS, simple partial seizure; VPA, valproate.
DISCUSSION
Virtually all AEDs have been used in the treatment
of SME usually with no clear results. Generally,
valproic acid (VPA) is considered to be the most
effective, though its actual efficacy has not been
confirmed. Among newer AEDs, vigabatrin increased
myoclonic seizures and lamotrigine has no significant
effects, though it has been reported that it can increase
seizures15. The use of IVIG at 100–200 mg kg−1
every 15 days to a total of six doses substantially
improved the outcome of seizures in 30% of cases3.
Improvement after puberty has been described16 but
not found in our series. Topiramate is the first oral
AED that achieved a significant reduction in the num-
ber of seizures. Burkart et al.17 reported 10% of
patients becoming seizure free and 60% of patients
showing a 50% reduction in seizure rate. These results
were slightly worse than ours (16% and 72%, respec-
tively).
Improvement was evident during dose escalation in
30% of the cases and in the stabilization stage in the
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Fig. 1: Response rate by seizure type. Abbreviations: ABS, absence seizure; CPS, complex partial seizure; GTCS, generalized
tonic–clonic seizure; MYOCL, myoclonic seizure; SPS, simple partial seizure.
rest. Adverse effects were moderate and transient.
This retrospective study suggests that TPM may be
effective in the treatment of SME in infancy and has a
specific role in the management of this epilepsy syn-
drome.
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